Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Novo Nordisk's ($NVO) new oral diabetes drug measured up to its injected counterpart in a midstage study, promising results the company heralds as a milestone in the field.
The drug, called OG217SC, is an oral version of Novo's semaglutide, now in Phase III development as a weekly subcutaneous treatment. Each acts as an analog of the hormone GLP-1 to promote the body's natural production of insulin, spurring weight loss and relieving the symptoms of Type 2 diabetes.
And the oral version did just that in Phase II, Novo said. In a 26-week, 600-patient trial designed to determine ideal doses for the drug, diabetics taking 40 mg of OG217SC--the highest dose--charted 1.9% reductions in blood A1C, which is a marker of glucose levels. By comparison, 1 mg of weekly injected semaglutide led to a 1.9% reduction, and placebo lowered A1C by .3%. Novo said the highest doses of the oral version also led to weight loss "comparable" with weekly semaglutide, which helped patients lose more than 14 pounds from a baseline of about 203.
http://www.fiercebiotech.com/story/...oral-diabetes-drug-clears-phase-ii/2015-02-20
Sounds interesting, Victoza in a pill 🙂
The drug, called OG217SC, is an oral version of Novo's semaglutide, now in Phase III development as a weekly subcutaneous treatment. Each acts as an analog of the hormone GLP-1 to promote the body's natural production of insulin, spurring weight loss and relieving the symptoms of Type 2 diabetes.
And the oral version did just that in Phase II, Novo said. In a 26-week, 600-patient trial designed to determine ideal doses for the drug, diabetics taking 40 mg of OG217SC--the highest dose--charted 1.9% reductions in blood A1C, which is a marker of glucose levels. By comparison, 1 mg of weekly injected semaglutide led to a 1.9% reduction, and placebo lowered A1C by .3%. Novo said the highest doses of the oral version also led to weight loss "comparable" with weekly semaglutide, which helped patients lose more than 14 pounds from a baseline of about 203.
http://www.fiercebiotech.com/story/...oral-diabetes-drug-clears-phase-ii/2015-02-20
Sounds interesting, Victoza in a pill 🙂